Basic Information
| LncRNA/CircRNA Name | TUC338 |
| Synonyms | NA |
| Region | GRCh38_12:53464468-53465057 |
| Ensemble | ENSG00000282977 |
| Refseq | NR_109828 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | qPCR, RNAi, Western blot, MTT assay etc. |
| Sample | HCC tissues, cell lines (HepG2, SMMC-7721, BEK-7402, Hep3B, and Huh-7) |
| Expression Pattern | up-regulated |
| Function Description | Higher levels of TUC338 were found both in HCC tissues and cell lines, knockdown of TUC338 was accompanied with increased expression of RASAL1 in HCC cell line with increased proliferation and invasion ability, knockdown of TUC338 could activate the RASAL1 pathway and inhibit tumor growth genes by directly targeting RASAL1 3'-UTR. Furthermore, knockdown of TUC338 in HepG2 sorafenib sensitized its reaction to the treatment of sorafenib, which was accompanied by increased expression RASAL1; intratumoral delivering of siTUC338 could also restore sorafenib treatment response in HepG2/Sor xenografts in vivo. |
| Pubmed ID | 27878301 |
| Year | 2017 |
| Title | Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1. |
External Links
| Links for TUC338 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |